DUKE MYCOLOGY
RESEARCH UNIT
Faculty and Research
Thomas G. Mitchell, PhD
Associate Professor
Department of Molecular Genetics and Microbiology
Director, Molecular Mycology and Pathogenesis Training Program (MMPTP)
Overview. The AIDS epidemic and the expanded use of immunosuppressive
therapies have accelerated a global increase in the incidence of systemic fungal
infections. The most prevalent opportunistic mycoses are caused by species of
Candida, Aspergillus, and Cryptococcus neoformans. As a result of
this mycological crisis, there is a pressing need to improve the accuracy and
speed of the diagnosis, to identify the sources of individual cases and outbreaks,
to develop fungal targets for intervention, and to understand the genetics and
distribution of populations of pathogenic fungi. Hence, there is a crucial need
for rapid and accurate methods to (1) identify fungal pathogens, (2) determine
the origin of a mycotic infection, (3) resolve the status of problematic species,
(4) track the transmission of strains involved in nosocomial mycoses, (5) recognize
strains with clinically important phenotypes, such as the expression of virulence
factors or resistance to antifungal drugs, and (6) clarify the origin(s) of diversity
and the population genetics of the major pathogens. The Medical Mycology Research
Laboratory has developed DNA-based approaches to address these issues and focused on
Candida species and C. neoformans.
C. albicans. To conduct rigorous population studies of
Candida albicans, we developed methods for genetic typing, such as
single-locus markers based on restriction fragment polymorphisms of amplified
products (PCR-RFLP). Genotypic frequencies at several of these co-dominant,
single-copy loci deviated significantly from random predictions, suggesting the
existence of a mechanism for recombination. These studies confirmed that
C. albicans is diploid and that substantial heterozygosity exists in natural
populations.
C. neoformans. The epidemiological and evolutionary relationships
among isolates of C. neoformans from nature and from patients are not well
understood. Isolates from a variety of sources are being analyzed using defined
genetic markers, such as PCR-RFLP, amplified fragment length polymorphisms, and
single nucleotide polymorphisms identified by sequencing genes and microsatellites.
These studies are designed to elucidate patterns of genetic variation, recombination,
and migration among populations and to identify specific genotypes that represent
lineages that have significantly diverged with respect to clinically relevant phenotypes.
Research Strategy. Regardless of the method used to assess virulence, most
species of pathogenic microorganisms exhibit strain variation in virulence. There are
three paradigmatic approaches to investigate microbial pathogenicity: (1) Researchers
can focus on a small number of genes in a small number of laboratory strains, mutants,
and constructs to isolate and elucidate a particular protein or pathway that is
essential for virulence. This approach has been most successful for pathogens in which
virulence factors are well-established and confined to a few genes. In fungi,
pathogenicity is polygenic. While several properties are clearly essential for the
virulence of a given fungal species, they are not necessarily sufficient. (2) Other
methods, such as differential display, in vivo expression technology, and more recently,
genomics and microarrays, have been used to identify multiple genes whose expression is
regulated under conditions of infection. These studies also usually involve one or a
few strains of the pathogen. (3) Our alternative approach is to analyze well-defined
populations composed of numerous isolates to discover genotypes or lineages that are
associated with enhanced (or decreased) pathogenicity and important clinical attributes,
such as tissue tropisms or antifungal drug resistance. For example, we discovered that
samples of C. albicans from individuals with HIV are dominated by a small number
signature multilocus genotypes. In addition to predicting the pathogenetic potential of
a clinical isolate, this information benefits other researchers who focus on particular
strains and genes because it is crucial that they study isolates that represent the most
clinically relevant strains. With the expanding sequence databases of pathogenic yeasts,
we will be able to develop many more markers and refine the power of multilocus genotypes
to discriminate among strains that differ in their pathobiology, and ultimately, to
identify the responsible genes.